ALYREF (Aly/REF export factor): A potential biomarker for predicting cancer occurrence and therapeutic efficacy.

Autor: Zhao Y; Department of Hematology, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China., Xing C; Department of Hematology, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China., Peng H; Department of Hematology, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China; Hunan Key Laboratory of Tumor Models and Individualized Medicine, Changsha, Hunan 410011, China; Hunan Engineering Research Center of Cell Immunotherapy for Hematopoietic Malignancies, Changsha, Hunan 410011, China. Electronic address: penghongling@csu.edu.cn.
Jazyk: angličtina
Zdroj: Life sciences [Life Sci] 2024 Feb 01; Vol. 338, pp. 122372. Date of Electronic Publication: 2023 Dec 21.
DOI: 10.1016/j.lfs.2023.122372
Abstrakt: 5-Methylcytosine (m5C) methylation is present in almost all types of RNA as an essential epigenetic modification. It is dynamically modulated by its associated enzymes, including m5C methyltransferases (NSUN, DNMT and TRDMT family members), demethylases (TET family and ALKBH1) and binding proteins (YTHDF2, ALYREF and YBX1). Among them, aberrant expression of the RNA-binding protein ALYREF can facilitate a variety of malignant phenotypes such as maintenance of proliferation, malignant heterogeneity, metastasis, and drug resistance to cell death through different regulatory mechanisms, including pre-mRNA processing, mRNA stability, and nuclear-cytoplasmic shuttling. The induction of these cellular processes by ALYREF results in treatment resistance and poor outcomes for patients. However, there are currently few reports of clinical applications or drug trials related to ALYREF. In addition, the looming observations on the role of ALYREF in the mechanisms of carcinogenesis and disease prognosis have triggered considerable interest, but critical evidence is not available. For example, animal experiments and ALYREF small molecule inhibitor trials. In this review, we, therefore, revisit the literature on ALYREF and highlight its importance as a prognostic biomarker for early prevention and as a therapeutic target.
Competing Interests: Declaration of competing interest The authors declare no conflict of interest.
(Copyright © 2023. Published by Elsevier Inc.)
Databáze: MEDLINE
Externí odkaz: